Advanz Pharma (OTCMKTS:CXRXF) Trading Down 9.8%

Advanz Pharma Corp (OTCMKTS:CXRXF) shares traded down 9.8% during mid-day trading on Thursday . The stock traded as low as $5.02 and last traded at $5.50, 6,231 shares were traded during trading. An increase of 1,094% from the average session volume of 522 shares. The stock had previously closed at $6.10.

Several analysts have recently issued reports on the company. Zacks Investment Research lowered Advanz Pharma from a “hold” rating to a “sell” rating in a report on Monday, September 16th. ValuEngine lowered Advanz Pharma from a “strong-buy” rating to a “buy” rating in a report on Wednesday, October 2nd.

The company has a current ratio of 2.23, a quick ratio of 1.92 and a debt-to-equity ratio of 9.26. The firm has a fifty day moving average price of $10.11 and a 200-day moving average price of $12.70.

Advanz Pharma (OTCMKTS:CXRXF) last released its earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share (EPS) for the quarter. The company had revenue of $119.64 million for the quarter. Advanz Pharma had a negative return on equity of 93.24% and a negative net margin of 50.87%.

Advanz Pharma Company Profile (OTCMKTS:CXRXF)

ADVANZ PHARMA Corp., a specialty pharmaceutical company, through its subsidiaries, owns or licenses a portfolio of branded and generic prescription products. The company operates through two segments, Concordia International and Concordia North America. The Concordia International segment owns or licenses a portfolio of branded and generic prescription products to wholesalers, hospitals, and pharmacies.

Further Reading: How can investors invest in the Euro STOXX 50 Index?

Receive News & Ratings for Advanz Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advanz Pharma and related companies with MarketBeat.com's FREE daily email newsletter.